| 1 |
34270920 | Memantine exerts neuroprotective effects by modulating α-synuclein transmission in a parkinsonian model. | 2021 Oct |
2 |
| 2 |
34776984 | Imprecision in Precision Medicine: Differential Response of a Disease-Linked GluN2A Mutant to NMDA Channel Blockers. | 2021 |
3 |
| 3 |
32765929 | GRIN2A -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. | 2020 Dec |
4 |
| 4 |
30870728 | Identifying mutations in epilepsy genes: Impact on treatment selection. | 2019 May |
1 |
| 5 |
28095420 | Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology. | 2017 Jan |
1 |
| 6 |
24839611 | GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. | 2014 Mar 1 |
3 |
| 7 |
20955720 | Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. | 2011 Feb-Mar |
4 |
| 8 |
19371579 | Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. | 2009 Apr |
2 |